The overall goal of this study is to establish the therapeutic efficacy of the cytokine tumor necrosis factor (TNF) for leukemia, and to determine the mechanism of its anti-leukemia effects. TNF, a product of cells of the macrophage/monocyte series, is cytotoxic to many tumor cells in vitro and causes necrosis of solid transplantable tumors in mice. TNF also exerts profound effects on hematopoiesis and hematopoietic progenitors. On this basis, we evaluated the effects of TNF on murine, Friend virus-induced leukemia and found that the cytokine significantly suppresses leukemic erythropoiesis in vivo and causes disease regression in a substantial proportion of the leukemic animals. Combination of TNF with interferon-gamma (IFN-gamma) increased the incidence of leukemia regression. The mechanisms of these effects remain unknown.
The aims of this study include: 1) to determine whether TNF acts directly on leukemic cells to cause regression of the disease; 2) to determine whether TNF causes leukemia regression by acting through effects on host T cells or macrophages; 3) to further evaluate the synergism between TNF and IFN-gamma and determine whether this occur: by direct action on leukemic cells or through T cells and macrophages; and, 4) to determine whether the effects of TNF on normal hematopoietic progenitors occurs by direct interaction or through production of mediators by mature hematopoietic cells. These studies will be carried out using the Friend virus-induced erythroleukemia a model system that is extensively characterized and highly manipulable. Macrophage and T cell function are known to influence the course of this disease. The results of this study could provide a rational basis for the use of TNF therapy of leukemias and related diseases.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA045674-01A1
Application #
3188847
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1988-07-01
Project End
1991-06-30
Budget Start
1988-07-01
Budget End
1989-06-30
Support Year
1
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Amc Cancer Research Center
Department
Type
DUNS #
City
Denver
State
CO
Country
United States
Zip Code
80214
McElwain, M C; Modzelewski, R A; Yu, W D et al. (1997) Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma. Am J Otolaryngol 18:293-8
Pourbohloul, S C; Thurlow, S M; Furmanski, P et al. (1992) Induction of permanent regression of Friend virus (FV) leukemia by adoptive transfer of T helper and not T cytotoxic cells. Leuk Res 16:881-7
Chang, M J; Pourbohloul, S C; Yu, W D et al. (1992) Differential effect in vitro of tumor necrosis factor-alpha (TNF) on normal and virus-infected erythroid progenitors from Friend virus (FVA)-infected mice. Exp Hematol 20:1271-7
Johnson, C S; Pourbohloul, S C; Furmanski, P (1991) Negative regulators of in vivo erythropoiesis: interaction of IL-1 alpha and TNF-alpha and the lack of a strict requirement for T or NK cells for their activity. Exp Hematol 19:101-5
Johnson, C S; Chang, M J; Braunschweiger, P G et al. (1991) Acute hemorrhagic necrosis of tumors induced by interleukin-1 alpha: effects independent of tumor necrosis factor. J Natl Cancer Inst 83:842-8
Furmanski, P; Johnson, C S (1990) Macrophage control of normal and leukemic erythropoiesis: identification of the macrophage-derived erythroid suppressing activity as interleukin-1 and the mediator of its in vivo action as tumor necrosis factor. Blood 75:2328-34
Johnson, C S; Chang, M J; Thurlow, S M et al. (1990) Immunotherapeutic approaches to leukemia: the use of the Friend virus-induced erythroleukemia model system. Cancer Res 50:5682S-5686S
Johnson, C S; Braunschweiger, P G; Furmanski, P (1990) In vivo effects of recombinant human and murine interleukin-1 alpha (IL-1 alpha) on murine hematopoiesis. In Vivo 4:93-6
Johnson, C S; Cook, C A; Furmanski, P (1990) In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO). Exp Hematol 18:109-13